Bachelor of Science in Human Biology

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Retrieved on: 
星期三, 十一月 1, 2023
CSU, Eli Lilly and Company, Trial of the century, Sangamo Therapeutics, Trustee, Onyx Pharmaceuticals, Leo Pharma, Acquisition, Connetable (Gatchina), MBA, BIO, CD117, Syndrome, Bachelor of Science in Human Biology, Rest, Growth, Biotechnology Innovation Organization, Risk, Methodist University, Partnership, Southern Methodist University, Pharmacy, Chairperson, Pleasure, University, Eli Lilly, Therapy, Patient, Management, Jasper, Science, Pardes

Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.

Key Points: 
  • Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.
  • “We are pleased to welcome Tom to our Board as Chairperson.
  • “I will be supporting Tom, Ron, and the rest of Jasper as I transition off the Jasper Board to new company ventures.”
    Mr. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
  • He began his career with Eli Lilly & Co. Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., and Cymabay Therapeutics Inc.

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

Retrieved on: 
星期一, 十一月 6, 2023
Auxilium, GCGR, Research and Development Council of New Jersey, Research, Medical college, IND, Glucagon-like peptide-1 receptor, Physician, GPR119, GSK plc, Development, Oxyntomodulin, Endo International, Ferring Pharmaceuticals, Johns Hopkins, NASH, Medicine, Biology, Ursinus College, OXM, Obstetrics, Tursi, Drexel University College of Medicine, GLP1R, Chemistry, Fatty liver disease, Bachelor of Science in Human Biology, Johns Hopkins Hospital, Investigational New Drug, Pharmaceutical industry, Gynaecology

Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.

Key Points: 
  • Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.
  • "James is a proven leader, with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," stated Andrew I. Koven, Chairman of NeuroBo's Board of Directors.
  • As such, I look forward to working closely with the NeuroBo leadership team and my fellow Directors to maximize the potential for the Company's next generation pharmaceuticals to treat cardiometabolic diseases."
  • Previously, from April 2020 until January 2022, Dr. Tursi was Chief Scientific Officer U.S. for Ferring Pharmaceuticals.

Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer

Retrieved on: 
星期一, 十月 30, 2023
Technology, Biotechnology, Health, Neurology, Consumer, Pharmaceutical, Research, Medical Devices, Software, Hardware, Science, Seniors, Data Management, Clinical Trials, Lopez v. River Oaks Imaging & Diagnostic Group, Inc., CCO, CNS, Howell, Cognito, Multimedia, Partnership, United States Department of the Navy, Therapy, Alzheimer's disease, Patient, Medtronic, Bachelor of Science in Human Biology, Tulane University, Nursing

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as Chief Commercial Officer (CCO).

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as Chief Commercial Officer (CCO).
  • View the full release here: https://www.businesswire.com/news/home/20231030288290/en/
    “Christian is an accomplished leader with a strong track record building commercial teams and driving global commercial launches in the medical device industry,” said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics.
  • Howell is a former Officer in the United States Navy and holds a Bachelor of Science degree from Tulane University.
  • "I'm excited to be joining Cognito and for the opportunity to support its mission to advance disease-modifying therapies for patients with neurodegenerative diseases," said Christian Howell, Chief Commercial Officer for Cognito Therapeutics.

Proactive Worldwide Welcomes Two Strategic Hires to Enhance Its Competitive Intelligence Operations

Retrieved on: 
星期一, 十月 30, 2023
Knowledge, Allergy, Yoder, Avery, Intelligence, Political science, Headache, CPG, Hematology, Dermatology, Insurance industry in China, Nephrology, Customer retention, Research, Prostate, Crohn's disease, Lung, University, PWW, Asthma, Osteoporosis, Human voice, Melanoma, Alzheimer's disease, Pain, Moses Austin, Bachelor of Science in Human Biology, Bachelor of Arts in Organizational Psychology, Fortune 500, Retail, Pharmaceutical industry, Insurance

SCHAUMBURG, Ill., Oct. 30, 2023 /PRNewswire/ -- In a strategic move to accommodate the increased demand for their competitive research and analysis services, Proactive Worldwide (PWW) is thrilled to announce the onboarding of two new senior analysts, Heather Yoder and Avery Ekman. These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.

Key Points: 
  • These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.
  • Dr. Heather Yoder shifted from the medical field into the realm of pharmaceutical competitive intelligence.
  • Her experience spans over 10 years, with remarkable achievements in primary and secondary research, analysis, as well as project management.
  • Their combined expertise will further ensure that our clients continue to receive actionable insights and value, backed by extensive research and analysis."

Market Access Veteran Ellen Cappellino Joins Klick Health

Retrieved on: 
星期四, 十月 26, 2023
Managed Care, General Health, Social Media, Professional Services, Search Engine Marketing, Digital Marketing, Public Relations, Investor Relations, Marketing, Advertising, Communications, Consulting, Health, AstraZeneca, Social media, Human, ChatGPT, Wyeth, News, MBA, Research, Albany College of Pharmacy and Health Sciences, Pfizer, Digital health, Caregiver, Type 2 diabetes, Click, Market access, Mayo Clinic Proceedings, Vertex Pharmaceuticals, AI, Patient, Bachelor of Science in Human Biology, Management, Pharmaceutical industry, Access, Giovanni Domenico Cappellino, New York University

Klick Health today announced that admired market access professional Ellen Cappellino has joined the agency to further build out its value, access, and reimbursement capabilities and help transform the healthcare experience for patients.

Key Points: 
  • Klick Health today announced that admired market access professional Ellen Cappellino has joined the agency to further build out its value, access, and reimbursement capabilities and help transform the healthcare experience for patients.
  • Klick Chief Medical Officer Holly Henry said Cappellino has the scientific background, clinical comprehension, and market access expertise they were looking for in a leader who can both develop the value story and generate maximum value for clients using health economics and outcomes research and real-world data.
  • Having worked within a variety of pharmaceutical organizations, Henry added that Cappellino is also a seasoned pro when it comes to approaching market access with a client-side perspective in mind.
  • “We are excited that Ellen has joined our growing Market Access team as we supercharge our Value, Access, and Reimbursement offering,” Henry said.

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

Retrieved on: 
星期四, 十月 19, 2023
CORAL, AstraZeneca, SVKM's NMIMS, TAP Pharmaceuticals, Rich, Catalyst (nonprofit organization), Notre Dame, Rare, Biotechnology, Takeda, Laboratory, Neuralstem, Inc., Diabetes, MBA, Catalyst Pharmaceuticals, Abbott Laboratories, Senior, Executive, University, Kellogg School, Metreleptin, Culture, Patient, Marketing, Bachelor of Science in Human Biology, Central nervous system, Management, Pharmaceutical industry, Science, Catalysis, Lipodystrophy

Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst.

Key Points: 
  • Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst.
  • "Today's announcement paves the way for a seamless transition for the new CEO at Catalyst.
  • "I am honored to serve as Catalyst's new CEO at such a pivotal point in the Company's evolution," said Richard J. Daly.
  • Prior to his appointment at Catalyst, Mr. Daly served as President of CARsgen Therapeutics Corporation since January 2022.

The Inner Circle Acknowledges, Sharon E. Oster, MD as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases

Retrieved on: 
星期一, 十月 9, 2023
ID, Infection, Internal medicine, Bachelor of Science in Human Biology, United States Department of Veterans Affairs, MD, Society, University, Inner circle, American Board of Commissioners for Foreign Missions, Love, Phi Beta Kappa, American Board of Internal Medicine, Tuskegee Veterans Administration Medical Center, ASM, AIDS, Davis, Medical Center, Patient, University of Colorado School of Medicine, Pharmaceutical industry, Medicine

BOISE, Idaho, Oct. 9, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.

Key Points: 
  • BOISE, Idaho, Oct. 9, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases.
  • She followed this accomplishment at East Virginia Medical School where she completed a medical degree in 1980.
  • Recognized as the Resident of the Year award, the doctor completed her residency at the Veterans Administration (VA) Medical Center.
  • Considered a leader in her field, Dr. Oster is considered an expert in internal medicine and infectious diseases.

Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

Retrieved on: 
星期三, 十月 4, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Odyssey, Abstract, GSK, Bachelor of Science in Human Biology, University, Boston University Chobanian & Avedisian School of Medicine, Emergency medicine, Biochemistry, Internal medicine, Upadacitinib, Lead, Multimedia, Rheumatology, Rheumatoid arthritis, Boston University School of Public Health, Stanford University School of Medicine, Medical research, Vaccine, Division, AbbVie, VA Palo Alto Health Care System, Faculty, Immunology, Pharmacology, Therapy, Boston Medical Center, Giant cell arteritis, Stanford University Medical Center, Inflammation, Pharmaceutical industry, Nursing, Science

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
  • In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets.
  • View the full release here: https://www.businesswire.com/news/home/20231004996667/en/
    Jeremy Sokolove, M.D., Chief Medical Officer of Odyssey Therapeutics, Inc. (Photo: Business Wire)
    “As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • “It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove.

GreenShield welcomes Sabrina Ladha as Vice President, GreenShield Cares

Retrieved on: 
星期一, 十月 2, 2023
Bachelor of Science in Human Biology, University, Social impact, Health, Harvard University, University of Texas at Austin, Mental health, UNC-Chapel Hill Master of Public Administration, Woman, Inter-State Bus Terminals, Government, Ladha, Business administration, Essential medicines, CSV, Dentistry, Harvard Kennedy School, Creating shared value, Growth, Master of Business Administration, Management, Science, Western University, Greenshields

TORONTO, Oct. 2, 2023 /CNW/ - GreenShield is pleased to announce the appointment of Sabrina Ladha as Vice President, Social Impact, GreenShield Cares.

Key Points: 
  • TORONTO, Oct. 2, 2023 /CNW/ - GreenShield is pleased to announce the appointment of Sabrina Ladha as Vice President, Social Impact, GreenShield Cares.
  • Through its social impact brand GreenShield Cares , the company reinvests its earnings and self-funds the deployment of its wholly-owned health services to support underserved and marginalized communities.
  • As part of GreenShield's transformational journey, Ladha will lead GreenShield Cares, with a focus on "Creating Shared Value" (CSV).
  • Through GreenShield Cares, the company reinvests its earnings and self-funds the deployment of its wholly owned health services to support underserved and marginalized communities.

Dr. Laura M. Tiedemann, Esteemed Oculoplastics Surgeon, Joins OCLI Vision's Growing Team

Retrieved on: 
星期五, 九月 29, 2023
Columbia University, Blepharoplasty, Bachelor of Science in Human Biology, University, Spanish National Health System, Boston Children's Hospital, George Washington University School of Medicine & Health Sciences, Orbit (anatomy), University of Pittsburgh Medical Center, Ophthalmology, Author, Research, Learning, NYU Langone Health, New York Medical College, Child, MD, Patient, Brown University, Internal medicine, Outline of health sciences, Spectrum, Hospital, Health, Yale New Haven Hospital, Filler (linguistics), Westchester Medical Center, Family, Dentistry, Nursing, Science, Neuroscience

GARDEN CITY, N.Y., Sept. 29, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to welcome Laura M. Tiedemann, MD, to their esteemed team of ophthalmologists. Dr. Tiedemann is a highly skilled and compassionate oculoplastics surgeon who brings her extensive expertise and dedication to patient care to the OCLI family. "As a New Jersey native, I am excited to join OCLI Vision and return to the tri-state area," Dr. Tiedemann shared. "Providing exceptional care to my patients has always been a passion of mine, and I am eager to make a meaningful impact on the eye health of my community."

Key Points: 
  • Esteemed oculoplastics surgeon Dr. Laura M. Tiedemann has joined OCLI Vision, specializing in minimally invasive cosmetic and reconstructive eye treatments.
  • GARDEN CITY, N.Y., Sept. 29, 2023 /PRNewswire-PRWeb/ -- OCLI Vision is proud to welcome Laura M. Tiedemann, MD, to their esteemed team of ophthalmologists.
  • Dr. Tiedemann is a highly skilled and compassionate oculoplastics surgeon who brings her extensive expertise and dedication to patient care to the OCLI family.
  • "As a New Jersey native, I am excited to join OCLI Vision and return to the tri-state area," Dr. Tiedemann shared.